Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-11-24

Clinical Trial Update: Long-term Study of KAD-1229 in Type 2 Diabetes Patients [Phase 3]

View source ↗

Summary

A long-term Phase 3 study of KAD-1229 in patients with Type 2 diabetes mellitus has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KAD-1229

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2014-11-24